Breckenridge announced that the FDA has approved its Abbreviated New Drug Application (ANDA) for Rizatriptan Benzoate Tablets, the generic version of Merck‘s Maxalt. Maxalt is a selective 5-HT1B/1D receptor agonist indicated for the acute treatment of migraine.
Maxalt is presumed to exert its therapeutic effects in the treatment of migraine headache by binding to the receptors located on intracranial blood vessels and sensory nerves of the trigeminal system.
Rizatriptan Benzoate is available in 5mg and 10mg dosage strength tablets. Breckenridge has begun shipping this product.
For more information call (561) 443-3314 or visit www.bpirx.com.